← Back to Search

Monoclonal Antibodies

Erenumab for Facial Pain

Phase 4

Waitlist Available

Led By David Jang, MD

Research Sponsored by David Jang, M.D.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 1, 3 and 6 months

Awards & highlights

Pivotal Trial

Drug Has Already Been Approved

Summary

This trial tests a medication that is given regularly to people with facial pain or pressure but no sinusitis. The medication works by blocking pain signals to reduce discomfort.

Eligible Conditions

Facial Pain
Sinusitis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 1,3, and 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 1,3, and 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 1,3, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in Mean Number of Days Per Month With Significant Mid-facial Pain or Pressure

Secondary study objectives

Change From Baseline in Mean Daily Pain Score

Change in Emotional Function as Measured by Migraine Function Impact Questionnaire (MFIQ)

Change in Mean Number of Days Per Month With Significant Nasal Congestion

+7 more

Awards & Highlights

Pivotal Trial

The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Drug Has Already Been Approved

The FDA has already approved this drug, and is just seeking more data.

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: ErenumabActive Control1 Intervention

140mg Erenumab administered by subcutaneous injection (in the abdomen, thigh, or upper arm), once monthly for six months.

Group II: PlaceboPlacebo Group1 Intervention

Placebo administered by subcutaneous injection (in the abdomen, thigh, or upper arm), once monthly for six months.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

David Jang, M.D.Lead Sponsor

AmgenIndustry Sponsor

1,433 Previous Clinical Trials

1,395,113 Total Patients Enrolled

David Jang, MD4.76 ReviewsPrincipal Investigator - Duke Health

Duke University

5Patient Review

Dr. Jang is extremely knowledgable and kind. He listened to me attentively and described the procedure and every component in detail. He clearly cares a great deal about his patients' well-being and I would recommend him wholeheartedly.